Athenex將在2018 RBC Capital Markets醫療護理大會上發表演說
February 16, 2018 15:18 ET
|
Athenex, Inc.
紐約州水牛城, Feb. 17, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (納斯達克:ATNX) 是一家致力於發現、開發以及將癌症及相關疾病新療法商業化的全球生物製藥公司。公司今天宣佈，行政總裁劉耀南博士將於2017年2月21日（星期三）美國東部時間上午11時正在紐約市舉行的2018 RBC Capital Markets醫療護理大會上發表演說。 ...
Athenex to Present at 2018 RBC Capital Markets Healthcare Conference
February 16, 2018 08:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex實現轉移性乳腺癌三期臨床試驗受試者招募目標，計劃在2018年第三季度進行第二次中期分析
February 15, 2018 17:32 ET
|
Athenex, Inc.
美國紐約州水牛城, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. ﹙Nasdaq:ATNX﹚是一間環球性的生物醫藥公司，致力於發掘、研發及商業化新型療法以治療癌症和相關病症。今日，Athenex, Inc.公布公司已實現受試者招募目標，讓公司得以在2018年第三季度對Oraxol KX-ORAX-001三期臨床試驗進行第二次中期分析。 ...
Athenex Meets Enrollment Target for Oraxol Phase III Clinical Trial in Metastatic Breast Cancer
February 15, 2018 08:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the...
Athenex 宣佈治療光化性角化病的KX2-391軟膏的兩項第三期臨床研究提前完成患者招募
February 14, 2018 18:28 ET
|
Athenex, Inc.
紐約州水牛城, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc.﹙Nasdaq：ATNX﹚是一家致力於發現、開發以及將癌症及相關疾病新療法商業化的全球生物製藥公司。該公司今天宣佈，治療光化性角化病（actinic keratosis）的KX2-391軟膏的兩項第三期臨床研究已完成患者招募，較原定時間早數個月。 ...
Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis
February 14, 2018 08:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex宣佈503B和特殊注射劑業務部門最近推出新產品
February 13, 2018 15:50 ET
|
Athenex, Inc.
紐約州水牛城, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (納斯達克:ATNX)...
Athenex Announces Recent Product Launches in 503B and Specialty Injectables Business Units
February 13, 2018 08:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex, Inc.宣佈普通股的發售價
January 25, 2018 15:02 ET
|
Athenex, Inc.
紐約州水牛城, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Athenex,...
Athenex, Inc. Announces Pricing of Offering of Common Stock
January 25, 2018 07:00 ET
|
Athenex, Inc.
BUFFALO, N.Y., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the...